
Cartha powers 0xMarkets, a wallet-based trading system where users can try crypto, currency, and commodity markets through a public web app, while advanced users can also supply capital through a separate dashboard.
Cartha is best understood as the capital-and-risk engine behind 0xMarkets. Traders use 0xMarkets to open leveraged positions, while capital providers supply liquidity to support those markets. The target users are traders, advanced liquidity providers, and technical operators. This is not a simple consumer app: the capital-supply side is especially advanced and includes risks around collateral, lockups, operator behavior, and market volatility. The product is live, with a public trading app, liquidity dashboard, documentation, open-source tooling, legal pages, and public test environments. However, the consumer-facing app surface appears narrower than the full roadmap described in docs, which suggest broader cross-asset ambitions. Reliable public user count, customer count, revenue, and profit figures were not found. Project-reported testnet numbers are useful signals but not independently verified.
The target users are traders, advanced liquidity providers, and technical operators. This is not a simple consumer app: the capital-supply side is especially advanced and includes risks around collateral, lockups, operator behavior, and market volatility.
Reliable public user count, customer count, revenue, and profit figures were not found. Project-reported testnet numbers are useful signals but not independently verified.
Closest alternatives include Gains Network gTrade, Ostium, Hyperliquid, dYdX, and GMX. Cartha/0xMarkets appears ambitious because it combines a trading front end with a capital-provider interface and aims beyond crypto-only markets. It appears weaker in public proof, regulatory clarity, and maturity versus established trading venues.
Cartha/0xMarkets is a real, public, high-risk financial platform. It should be evaluated carefully through test flows first, especially because leverage, jurisdiction restrictions, and capital-provider risks are central to the product.